← All trials
NCT01894958
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2014
- Primary completion
- Sep 1, 2015
- Completion date
- Oct 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 72
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Neuren Pharmaceuticals LimitedLead sponsor
- Emory UniversityOverall official - principal investigator
- University of MichiganOverall official - principal investigator
- University of NebraskaOverall official - principal investigator
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.Overall official - principal investigator
- Rush UniversityOverall official - principal investigator
- University of WashingtonOverall official - principal investigator
- Baylor UniversityOverall official - principal investigator
- University of MassachusettsOverall official - principal investigator
- University of CincinnatiOverall official - principal investigator
- Greenwood Genetic CenterOverall official - principal investigator
- University of ColoradoOverall official - principal investigator
- Vanderbilt UniversityOverall official - principal investigator
- University of California, DavisOverall official - principal investigator
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
- Geisinger ClinicOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.